Table 1 Baseline and therapeutic characteristics of patients before and after propensity score matching
Characteristics | Before matching (%) | After matching (%) | ||||
|---|---|---|---|---|---|---|
PCI (n = 440) | Active surveillance (n = 628) | p value | PCI (n = 324) | Active surveillance (n = 324) | p value | |
Age, median (IQR), y | 57 (51–63) | 59 (52–64) | 0.029 | 58 (51–64) | 59 (51–65) | 0.268 |
 < 65 | 356 (80.9) | 473 (75.3) | 0.031 | 255 (78.7) | 240 (74.1) | 0.165 |
 ≥ 65 | 84 (19.1) | 155 (24.7) |  | 69 (21.3) | 84 (25.9) |  |
Gender | ||||||
 Male | 312 (70.9) | 434 (69.1) | 0.528 | 232 (71.6) | 229 (70.7) | 0.795 |
 Female | 128 (29.1) | 194 (30.9) |  | 92 (28.4) | 95 (29.3) |  |
ECOG PS | ||||||
 0 | 52 (11.8) | 91 (14.5) | 0.427 | 41 (12.7) | 39 (12) | 0.609 |
 1 | 371 (84.3) | 511 (81.4) |  | 272 (84) | 269 (83) |  |
 2 | 17 (3.9) | 26 (4.1) |  | 11 (3.4) | 16 (4.9) |  |
Smoking status | ||||||
 Never | 188 (42.7) | 263 (41.9) | 0.831 | 138 (42.6) | 139 (42.9) | 0.762 |
 Former | 40 (9.1) | 64 (10.2) |  | 27 (8.3) | 32 (9.9) |  |
 Current | 212 (48.2) | 301 (47.9) |  | 159 (49.1) | 153 (47.2) |  |
Disease stage | ||||||
 I–II | 88 (20) | 102 (16.2) | 0.114 | 62 (19.1) | 54 (16.7) | 0.412 |
 III | 352 (80) | 526 (83.8) |  | 262 (80.9) | 270 (83.3) |  |
Surgery | ||||||
 Yes | 31 (7) | 54 (8.6) | 0.356 | 29 (9) | 28 (8.6) | 0.89 |
 No | 409 (93) | 574 (91.4) |  | 295 (91) | 296 (91.4) |  |
Chemotherapy | ||||||
 Etoposide + platinum | 428 (97.3) | 601 (95.7) | 0.12 | 315 (97.2) | 309 (95.4) | 0.212 |
 Others | 11 (2.5) | 27 (4.3) |  | 9 (2.8) | 15 (4.6) |  |
CRT sequence | ||||||
 Sequential | 243 (55.2) | 452 (72) | < 0.001 | 209 (64.5) | 192 (59.3) | 0.169 |
 Concurrent | 197 (44.8) | 176 (28) |  | 115 (35.5) | 132 (40.7) |  |
Response to CRT | ||||||
 PR | 296 (67.3) | 464 (73.9) | 0.019 | 233 (71.9) | 225 (69.4) | 0.49 |
 CR | 144 (32.7) | 164 (26.1) |  | 91 (28.1) | 99 (30.6) |  |